For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 0 | |||
| Research and development | 11,029,000 | |||
| General and administrative | 10,902,000 | |||
| Impairment loss on intangible assets | 28,700,000 | |||
| Total operating expenses | 50,631,000 | |||
| Loss from operations | -50,631,000 | |||
| Other income, net | 48,000 | |||
| Income tax benefit | -712,000 | |||
| Net loss | -49,871,000 | |||
| Unrealized (loss) gain on investments, net of tax of 0 | -15,000 | |||
| Foreign currency translation adjustments | -29,000 | |||
| Total other comprehensive (loss) gain | -44,000 | |||
| Total comprehensive loss | -49,915,000 | |||
| Basic EPS | -1.96 | |||
| Diluted EPS | -1.96 | |||
| Basic Average Shares | 25,444,795 | |||
| Diluted Average Shares | 25,444,795 | |||
Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc. (RNTX)